Find your next paid study

Pancreatic Neuroendocrine Neoplasm

~$75 – $3,000

Actual pay is set by the research site.

Gulam ManjiNCT06048484

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating loca…

University of California, San FranciscoNCT05746182

~$10 – $675

Actual pay is set by the research site.

Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data

This research will leverage machine learning (ML) and causal inference techniques applied to real-world data (RWD) to generate evidence that personalizes treat…

Non-small Cell Lung Cancer

University of UtahNCT06934343

Actual pay is set by the research site.

Diabetes Mellitus, Type 1

Islet Transplantation in Patients With "Brittle" Type I Diabetes

The purpose of this study is to learn about the safety of islet transplantation for Type 1 diabetes mellitus, which may provide more normal control of blood su…

University of ChicagoNCT01630850

Actual pay is set by the research site.

Phase 2

A Phase 2, Long-term Extension Study of the Safety and Efficacy of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia Who Completed a Sponsored ORX750 Clinical Trial

This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 i…

Narcolepsy Type 1Narcolepsy Type 2Idiopathic Hypersomnia

Centessa Pharmaceuticals (UK) LimitedNCT07096674

~$75 – $2,800

Actual pay is set by the research site.

Phase 2

A Pilot Clinical Trial of Vemurafenib and Cobimetinib as a Redifferentiation Strategy in High-Risk, Radioactive Iodine (RAI) Naïve, BRAFV600E Mutated Differentiated Thyroid Carcinoma Patients Undergoing Initial RAI Therapy

This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutatio…

Thyroid Gland Follicular CarcinomaThyroid Gland Oncocytic CarcinomaThyroid Gland Papillary Carcinoma

City of Hope Medical CenterNCT06440850

~$75 – $2,000

Actual pay is set by the research site.

Exercise OncologyPhysical Activity BehaviorBehavior Change Interventions

An Adaptive Physical Activity Maintenance Intervention

The goal of this clinical trial is to develop and test an adaptive physical activity (PA) maintenance intervention for cancer survivors, after participating in…

Colorado State UniversityNCT06359210

Actual pay is set by the research site.

The Effect of Exercise on Patient Outcomes During Treatment of Soft Tissue Sarcoma With Neoadjuvant Radiation Therapy and Surgical Resection

The purpose of this study is to evaluate the effect of a neoadjuvant (i.e. pre-treatment) exercise regimen on extremity function and postoperative wound healin…

Soft Tissue Sarcoma

Duke UniversityNCT04921917

Actual pay is set by the research site.

Phase 1

Cromoglicte Adjunctive Therapy for Outpatients With Schizophrenia

This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate.

SchizophreniaSchizo Affective Disorder

Vishwajit Nimgaonkar, MD PhDNCT03794076

~$150 – $4,500

Actual pay is set by the research site.

Global Cardio Oncology Registry

G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of …

Breast CancerHematologic MalignancyImmune Checkpoint Inhibitor-Related Myocarditis+2 more

The Cleveland ClinicNCT05598879

Actual pay is set by the research site.

Amyloidosis, PrimaryCardiomyopathy

Molecular Imaging of Primary Amyloid Cardiomyopathy

Cardiac amyloidosis is a major cause of early treatment-related death and poor overall survival in individuals with systemic light chain amyloidosis. This proj…

Brigham and Women's HospitalNCT02641145

Actual pay is set by the research site.

A Phase II Study of Total Consolidative Metastasis-and-primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC).

This is a non-randomized, open-label phase II study designed to estimate 12-month treatment-free survival rate following total consolidative metastasis-and-pri…

Renal Cell Carcinoma